Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Technologies, Thomas Scientific Ink Distribution Agreement for Genomics Products

NEW YORK ─ Thomas Scientific said on Tuesday that it has inked a strategic distribution agreement with Agilent Technologies that expands its molecular biology product portfolio.

Under the deal, Thomas Scientific will provide its customers with access to more than 700 bioreagent products from the genomics division of Santa Clara, California-based Agilent, including qPCR instruments, PCR enzymes, and other molecular biology reagents. To help satisfy growing demands from high complexity laboratories, Agilent's CRISPR libraries will also be available through Thomas Scientific.

Financial and other terms of the deal were not disclosed.

Swedesboro, New Jersey-based Thomas Scientific noted that from the time of its acquisition by the Carlyle Group in 2017, it has completed four strategic acquisitions that have helped it expand the reach of its distribution network. It also has other distribution agreements, including with MicroGEM, Reditus Laboratories, and Microbix Biosystems.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.